BioLife Solns Analyst Ratings
H.C. Wainwright Initiates BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $29
Maxim Group Maintains BioLife Solutions(BLFS.US) With Buy Rating, Announces Target Price $30
BioLife Solns Analyst Ratings
Craig-Hallum Maintains Buy on BioLife Solns, Raises Price Target to $30
BioLife Solns Analyst Ratings
Northland Capital Markets Maintains Outperform on BioLife Solns, Raises Price Target to $28
BioLife Solutions (BLFS) Gets a Buy From Lake Street
Buy Rating Justified by BioLife Solutions' Strong Financial Position and Growth Prospects
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Craig-Hallum Maintains BioLife Solutions(BLFS.US) With Buy Rating
Analysts Conflicted on These Healthcare Names: BioLife Solutions (BLFS), Arvinas Holding Company (ARVN) and Natera (NTRA)
TD Cowen Maintains Buy on BioLife Solns, Raises Price Target to $26
BioLife Solns Analyst Ratings
BioLife Solutions: Strong Buy Rating on Robust Gross Margins and Positive Long-Term EBITDA Outlook
BioLife Solutions (BLFS) Receives a Buy From Craig-Hallum
Analysts Are Bullish on Top Healthcare Stocks: Fortress Biotech (FBIO), BioLife Solutions (BLFS)
Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and BioLife Solutions (BLFS)
BioLife Solns Analyst Ratings
Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target